Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Protein-Structure Assisted Optimization of 4,5-Dihydroxypyrimidine-6-Carboxamide Inhibitors of Influenza Virus Endonuclease

Journal Article · · Scientific Reports
; ; ; ; ; ; ; ; ;

Abstract not provided.

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
National Institutes of Health (NIH)
OSTI ID:
1462573
Journal Information:
Scientific Reports, Vol. 7, Issue 1; ISSN 2045-2322
Publisher:
Nature Publishing Group
Country of Publication:
United States
Language:
ENGLISH

References (43)

Dihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase Inhibitors May 2007
The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit February 2009
Global Mortality Impact of the 1957–1959 Influenza Pandemic February 2016
Structural Analysis of Specific Metal Chelating Inhibitor Binding to the Endonuclease Domain of Influenza pH1N1 (2009) Polymerase August 2012
Multinational Impact of the 1968 Hong Kong Influenza Pandemic: Evidence for a Smoldering Pandemic July 2005
Refinement of Macromolecular Structures by the Maximum-Likelihood Method May 1997
Crystallographic Fragment Screening and Structure-Based Optimization Yields a New Class of Influenza Endonuclease Inhibitors September 2013
Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease August 2012
Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor March 2016
Crystal structure of the RNA-dependent RNA polymerase from influenza C virus October 2015
WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013 August 2014
Identification of Influenza Endonuclease Inhibitors Using a Novel Fluorescence Polarization Assay January 2012
Features and development of Coot March 2010
Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection September 2008
Phenyl Substituted 4-Hydroxypyridazin-3(2 H )-ones and 5-Hydroxypyrimidin-4(3 H )-ones: Inhibitors of Influenza A Endonuclease September 2014
Fragment-Based Identification of Influenza Endonuclease Inhibitors June 2016
Antivirals for influenza: Historical perspectives and lessons learned September 2006
Discovery and Synthesis of HIV Integrase Inhibitors:  Development of Potent and Orally Bioavailable N-Methyl Pyrimidones October 2007
Synthesis of Natural Flutimide and Analogous Fully Substituted Pyrazine-2,6-diones, Endonuclease Inhibitors of Influenza Virus August 2001
Strategies of Development of Antiviral Agents Directed Against Influenza Virus Replication December 2007
Structure of influenza A polymerase bound to the viral RNA promoter November 2014
PA subunit of RNA polymerase as a promising target for anti-influenza virus agents June 2008
Two Distinctive Binding Modes of Endonuclease Inhibitors to the N-Terminal Region of Influenza Virus Polymerase Acidic Subunit April 2016
Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus December 2001
Favipiravir: A New Medication for the Ebola Virus Disease Pandemic December 2014
3-Hydroxyquinolin-2(1 H )-ones As Inhibitors of Influenza A Endonuclease May 2013
Use of a Pharmacophore Model To Discover a New Class of Influenza Endonuclease Inhibitors March 2003
The 1918 Spanish influenza:integrating history and biology January 2001
Structural and computational study on inhibitory compounds for endonuclease activity of influenza virus polymerase September 2015
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1 March 2001
Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2 July 2014
N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes August 2016
Current and novel antiviral strategies for influenza infection June 2016
[20] Processing of X-ray diffraction data collected in oscillation mode January 1997
Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. December 1994
Crystal structure of an avian influenza polymerase PAN reveals an endonuclease active site February 2009
When poor solubility becomes an issue: From early stage to proof of concept August 2007
Phaser crystallographic software July 2007
Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit December 2014
2-Substituted-4,5-Dihydroxypyrimidine-6-Carboxamide Antiviral Targeted Libraries November 2009
A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro July 2016
Recent Advances in Computer-Aided Drug Design as Applied to Anti-Influenza Drug Discovery October 2014
Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives February 2017

Similar Records

Related Subjects